Scientists have developed a new method to produce a key Parkinson’s disease drug using waste plastic bottles, according to a study from the University of Edinburgh. The process uses bacteria to convert post-consumer plastic into L-DOPA, a commonly used treatment for the neurological condition.

The breakthrough involves genetically engineered E. coli bacteria, designed by a team led by Dr. Stephen Wallace. These bacteria are able to break down polyethylene terephthalate (PET), a plastic widely used in food and drink packaging, and convert it into L-DOPA through a series of biological reactions. PET is first broken down into terephthalic acid, which then serves as the base for the transformation.

Researchers say this is the first time a fully biological process has been used to produce the drug from plastic waste. They believe the method could offer a more sustainable alternative to traditional pharmaceutical production, which often depends on fossil fuels.

Dr. Wallace described the development as an early step in unlocking new uses for plastic waste. He said materials often seen as environmental problems could instead become valuable resources for producing medicines and other important products.

The team also highlighted the growing need for better recycling solutions, noting that current systems are not fully effective and still contribute to global plastic pollution. L-DOPA, which helps increase dopamine levels in the brain, is widely used to treat Parkinson’s disease and other conditions such as Restless Leg Syndrome.

Join the Dadli News WhatsApp Group:  https://chat.whatsapp.com/L04JxtMbG39FLBbxYWlz9T